Aegle Therapeutics
Developing extracellular vesicle (EV) therapies to address rare and serious diseases and disorders
Woburn, United States
7 employees
Convertible Note
Total: $13.50M
Biotechnology, Health and Wellness
General Information
Get notified when Aegle Therapeutics moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Aegle Therapeutics
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biotechnology
About Aegle Therapeutics
Taxonomy: extracellular vesicles, EV therapies, stem cells, regenerative healing, immune modulation, dermatology, immunology, pediatric disorders, rare diseases, regenerative medicine, clinical-stage biotech, mesenchymal stem cells, regulatory clearance, Miami-based company
Funding Rounds & Investors (4)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Convertible Note | •••••• | 1 |
|
12 Apr 2022 |
| Series A | •••••• | 5 |
|
29 Sep 2020 |
| Series A | •••••• | 4 |
|
09 Jan 2020 |
| Seed Round | •••••• | - | 01 May 2018 |
Aegle Therapeutics Alternatives & Competitors
An unprecedented era of stem cell therapy has arrived!
Using mesenchymal stem cells to produce therapeutically meaningful extracellular vesicles.
Pioneering novel treatments for neurological diseases, advancing the way to effective remyelination...
FAQ About Aegle Therapeutics
Don't just browse. Track.
Signal Tracker monitors Aegle Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.